Daxor to Showcase Portable Blood Volume Analyzer at ACC.26, Highlighting Readmission Reductions
Event summary
- Daxor will exhibit its next-generation portable Blood Volume Analyzer (BVA) at ACC.26 in New Orleans from March 28–30, 2026.
- The BVA claims >95% accuracy in measuring blood volume, addressing the $3.5B annual Medicare burden of heart failure readmissions.
- Peer-reviewed studies show BVA-guided care reduces 30-day readmissions by 56% and mortality by 82%.
- Daxor operates a 20,000-square-foot U.S. manufacturing facility, positioning it for market expansion.
The big picture
Daxor’s portable BVA targets a critical gap in cardiovascular care, where imprecise fluid management contributes to costly readmissions. The technology aligns with the shift toward value-based healthcare, where reducing readmissions and mortality directly impacts reimbursement. The company’s ISO-certified manufacturing and FDA clearance position it for scaling in both inpatient and outpatient settings.
What we're watching
- Adoption Pace
- How quickly hospitals and clinics integrate the portable BVA into standard care protocols.
- Reimbursement Dynamics
- Whether Medicare and private payers expand coverage for BVA-guided treatments.
- Competitive Response
- The likelihood of rivals developing similar blood volume measurement technologies.
Related topics